Exploring the level of agreement among different drug-drug interaction checkers: a comparative study on direct oral anticoagulants.
Direct-acting oral anticoagulants
drug-drug interactions
interaction checkers
summary of product characteristics
Journal
Expert opinion on drug metabolism & toxicology
ISSN: 1744-7607
Titre abrégé: Expert Opin Drug Metab Toxicol
Pays: England
ID NLM: 101228422
Informations de publication
Date de publication:
22 Feb 2024
22 Feb 2024
Historique:
medline:
22
2
2024
pubmed:
22
2
2024
entrez:
22
2
2024
Statut:
aheadofprint
Résumé
Direct oral anticoagulants (DOACs) may be involved in drug-drug interactions (DDIs) potentially increasing the risk of adverse drug reactions. This study aimed to evaluate the level of agreement among interaction checkers (ICs) and DOACs' summary of product characteristics (SPCs), in listing DDIs and in attributing DDIs' severity. The level of agreement among five ICs (i.e. INTERCheck WEB, Micromedex, Lexicomp, Epocrates, and drugs.com) in identifying potential DDIs and in attributing severity categories was evaluated using Gwet's AC1 on all five ICs and by comparing groups of 4- and 2-pair sets of ICs. A total of 486 potentially interacting drugs with dabigatran, 556 for apixaban, 444 for edoxaban, and 561 for rivaroxaban were reported. The level of agreement among the ICs in identifying potential DDIs was poor (range: 0.12-0.16). Similarly, it was low in 4 and 2-sets analyses. The level of agreement among the ICs in classifying the severity of potential DDIs was poor (range: 0.32-0.34), also in 4 and 2-sets analyses. The heterogeneity among different ICs and SPCs underscores the need to standardize DDIs datasets and to conduct real-world studies to generate evidence regarding the frequency and clinical relevance of potential DOACs-related DDIs.
Sections du résumé
BACKGROUND
UNASSIGNED
Direct oral anticoagulants (DOACs) may be involved in drug-drug interactions (DDIs) potentially increasing the risk of adverse drug reactions. This study aimed to evaluate the level of agreement among interaction checkers (ICs) and DOACs' summary of product characteristics (SPCs), in listing DDIs and in attributing DDIs' severity.
RESEARCH DESIGN AND METHODS
UNASSIGNED
The level of agreement among five ICs (i.e. INTERCheck WEB, Micromedex, Lexicomp, Epocrates, and drugs.com) in identifying potential DDIs and in attributing severity categories was evaluated using Gwet's AC1 on all five ICs and by comparing groups of 4- and 2-pair sets of ICs.
RESULTS
UNASSIGNED
A total of 486 potentially interacting drugs with dabigatran, 556 for apixaban, 444 for edoxaban, and 561 for rivaroxaban were reported. The level of agreement among the ICs in identifying potential DDIs was poor (range: 0.12-0.16). Similarly, it was low in 4 and 2-sets analyses. The level of agreement among the ICs in classifying the severity of potential DDIs was poor (range: 0.32-0.34), also in 4 and 2-sets analyses.
CONCLUSIONS
UNASSIGNED
The heterogeneity among different ICs and SPCs underscores the need to standardize DDIs datasets and to conduct real-world studies to generate evidence regarding the frequency and clinical relevance of potential DOACs-related DDIs.
Identifiants
pubmed: 38386102
doi: 10.1080/17425255.2024.2322134
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM